The FDA has finally approved Novavax’s COVID-19 vaccine, but with unexpected restrictions that could impact its rollout. Discover what this means for public health and vaccination strategies.
The U.S. Department of Health and Human Services is on a bold mission to develop a universal flu vaccine within four years, a project that could revolutionize how we combat influenza and prepare for future pandemics. Funded by $500 million, this initiative aims for FDA approval by 2029, with clinical trials starting soon. Experts weigh in on the challenges and potential of this ambitious project.
Peter Marks, the FDA's Center for Biologics Evaluation and Research head, resigns amid growing concerns over measles outbreaks and vaccine misinformation. His exit raises alarms about future public health initiatives.
